National Institutes of Pharmaceutical Research and Development (China)

Pharmacokinetic and safety interactions between aildenafil and clarithromycin, cimetidine, or rifampin in healthy subjects

Aims Aildenafil citrate, an orally bioavailable phosphodiesterase type 5 (PDE5) inhibitor, is primarily metabolized by cytochrome P450 3A4 (CYP3A4). This study aimed to assess potential pharmacokinetic interactions between aildenafil citrate tablets and cytochrome P450 (CYP)3A mo...

Research Advances on Organelle-Targeted Drug Delivery Systems for the Treatment of Brain Tumors and Central Nervous System Inflammation

Central nervous system (CNS) inflammation and brain tumor treatment are constrained by the heterogeneity of the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB), as well as by the sequential barriers to drug delivery across lesions, target cells and subcellular orga...

Pharmacokinetics, pharmacodynamics and safety profile of tapentadol hydrochloride injection: a phase 1 dose-escalation study in patients with moderate to severe pain

Abstract An injectable formulation of tapentadol hydrochloride offers a promising alternative for clinical settings requiring rapid analgesia. However, comprehensive clinical data on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of intravenous tapentadol hydrochlor...